NASDAQ:POAI Predictive Oncology (POAI) Stock Forecast, Price & News $3.16 +0.04 (+1.28%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$3.05▼$3.2150-Day Range$2.96▼$6.2152-Week Range$2.47▼$13.88Volume9,926 shsAverage Volume25,989 shsMarket Capitalization$12.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Predictive Oncology (NASDAQ:POAI) StockPredictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.Read More POAI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart POAI Stock News HeadlinesSeptember 27, 2023 | americanbankingnews.comPredictive Oncology (NASDAQ:POAI) Stock Price Crosses Below 200-Day Moving Average of $4.56September 19, 2023 | americanbankingnews.comFinancial Review: Predictive Oncology (NASDAQ:POAI) vs. Opsens (OTCMKTS:OPSSF)September 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. August 12, 2023 | finance.yahoo.comPredictive Oncology Inc. (NASDAQ:POAI) Q2 2023 Earnings Call TranscriptAugust 11, 2023 | finanznachrichten.dePredictive Oncology Inc.: Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 11, 2023 | finance.yahoo.comPredictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 3, 2023 | finance.yahoo.comPredictive Oncology to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on Thursday, August 10, 2023July 18, 2023 | proactiveinvestors.comPredictive Oncology moves company headquarters to PittsburghSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."July 18, 2023 | finance.yahoo.comPredictive Oncology Announces Relocation of Corporate Headquarters to PittsburghJune 29, 2023 | finance.yahoo.comIs Predictive Oncology (NASDAQ:POAI) In A Good Position To Deliver On Growth Plans?June 27, 2023 | proactiveinvestors.comPredictive Oncology adds biopharmaceutical CFO Andrew Einhorn to business advisory boardJune 27, 2023 | finance.yahoo.comPredictive Oncology Appoints Biopharmaceutical Finance Veteran Mr. Andrew Einhorn to its Business Advisory BoardJune 20, 2023 | finance.yahoo.comPredictive Oncology Appoints Dr. Bernard A. Harris, Jr. to its Newly Formed Business Advisory BoardMay 23, 2023 | finance.yahoo.comPredictive Oncology invited to present groundbreaking approach to drug discovery at the 2023 BIO International ConventionMay 15, 2023 | finance.yahoo.comPredictive Oncology Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 10, 2023 | marketwatch.comAI Tools are Enhancing Inclusivity and Reducing Bias in Hiring ProcessesMay 9, 2023 | finanznachrichten.deFinancialBuzz.com: AI Tools are Enhancing Inclusivity and Reducing Bias in Hiring ProcessesMay 8, 2023 | finance.yahoo.comPredictive Oncology to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 15, 2023May 3, 2023 | marketwatch.comInvestorNewsBreaks - Predictive Oncology Inc. (NASDAQ: POAI) Appoints Seasoned Veteran as New Board MemberMay 3, 2023 | proactiveinvestors.comPredictive Oncology appoints healthcare commercial and business development veteran to its boardMay 2, 2023 | finance.yahoo.comPredictive Oncology Appoints Pharma, Biotech and Digital Health Veteran Veena Rao, PhD, MBA, to its Board of DirectorsApril 21, 2023 | msn.comWhy SAP Shares Are Trading Higher By Around 6%? Here Are Other Stocks Moving In Friday's Mid-Day SessionApril 21, 2023 | msn.comWhy Predictive Oncology Stock Is Getting HammeredApril 21, 2023 | finanznachrichten.dePredictive Oncology Inc.: Predictive Oncology Announces Reverse Stock SplitApril 20, 2023 | finance.yahoo.comPredictive Oncology Announces Reverse Stock SplitApril 4, 2023 | finance.yahoo.comPredictive Oncology Announces Appointment of Oncology Translational Research Leader Christoph Reinhard, Ph.D., MBA, to its Scientific Advisory BoardSee More Headlines Receive POAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address POAI Company Calendar Last Earnings8/10/2023Today9/27/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:POAI CUSIPN/A CIK1446159 Webwww.precisiontherapeutics.com Phone(651) 389-4800FaxN/AEmployees31Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,740,000.00 Net Margins-1,246.52% Pretax Margin-1,246.52% Return on Equity-90.72% Return on Assets-73.16% Debt Debt-to-Equity RatioN/A Current Ratio4.24 Quick Ratio4.14 Sales & Book Value Annual Sales$1.51 million Price / Sales8.43 Cash FlowN/A Price / Cash FlowN/A Book Value$5.53 per share Price / Book0.57Miscellaneous Outstanding Shares4,030,000Free Float3,937,000Market Cap$12.73 million OptionableNot Optionable Beta1.54 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Raymond F. Vennare (Age 70)CEO & Chairman Comp: $581.58kMr. Robert L. Myers M.B.A. (Age 68)CFO & Sec. Comp: $511.87kMs. Theresa FergusonSr. Director of MarketingDr. Pamela Bush M.B.A. (Age 49)Ph.D., Chief Bus. Officer Dr. Lawrence J. DeLucas D.ScO.D, Ph.D., Sr. VP of BiologicsDr. Arlette H. Uihlein FCAPM.D., Sr. VP of Translational Medicine & Drug Discovery and Medical DirectorMore ExecutivesKey CompetitorsNutribandNASDAQ:NTRBHeart Test LaboratoriesNASDAQ:HSCSNanoVibronixNASDAQ:NAOVSientraNASDAQ:SIENOceanTech Acquisitions INASDAQ:OTECView All CompetitorsInsiders & InstitutionsState Street CorpSold 232,495 shares on 8/14/2023Ownership: 0.304%Geode Capital Management LLCSold 613,724 shares on 8/11/2023Ownership: 0.814%Renaissance Technologies LLCSold 187,439 shares on 8/11/2023Ownership: 0.475%RB Capital Management LLCSold 395,858 shares on 8/8/2023Ownership: 0.525%Carnegie Mellon UniversitySold 196,786 shares on 8/1/2023Ownership: 0.261%View All Insider TransactionsView All Institutional Transactions POAI Stock - Frequently Asked Questions How have POAI shares performed in 2023? Predictive Oncology's stock was trading at $6.1320 on January 1st, 2023. Since then, POAI stock has decreased by 48.5% and is now trading at $3.16. View the best growth stocks for 2023 here. When is Predictive Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our POAI earnings forecast. How were Predictive Oncology's earnings last quarter? Predictive Oncology Inc. (NASDAQ:POAI) released its quarterly earnings results on Thursday, August, 10th. The medical instruments supplier reported ($0.95) earnings per share for the quarter. The medical instruments supplier had revenue of $0.49 million for the quarter. Predictive Oncology had a negative net margin of 1,246.52% and a negative trailing twelve-month return on equity of 90.72%. When did Predictive Oncology's stock split? Predictive Oncology shares reverse split on the morning of Monday, April 24th 2023. The 1-20 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Predictive Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Predictive Oncology investors own include NVIDIA (NVDA), OPKO Health (OPK), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Overstock.com (OSTK), Riot Platforms (RIOT), AcelRx Pharmaceuticals (ACRX), Boeing (BA), QUALCOMM (QCOM) and Sorrento Therapeutics (SRNE). What is Predictive Oncology's stock symbol? Predictive Oncology trades on the NASDAQ under the ticker symbol "POAI." Who are Predictive Oncology's major shareholders? Predictive Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.81%), RB Capital Management LLC (0.52%), Renaissance Technologies LLC (0.48%), State Street Corp (0.30%) and Carnegie Mellon University (0.26%). Insiders that own company stock include Carl I Schwartz, Charles Lee Sr Nuzum Sr, Daniel E Handley, J Melville Engle, Raymond F Vennare and Robert L Myers. View institutional ownership trends. How do I buy shares of Predictive Oncology? Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Predictive Oncology's stock price today? One share of POAI stock can currently be purchased for approximately $3.16. How much money does Predictive Oncology make? Predictive Oncology (NASDAQ:POAI) has a market capitalization of $12.73 million and generates $1.51 million in revenue each year. The medical instruments supplier earns $-25,740,000.00 in net income (profit) each year or ($4.84) on an earnings per share basis. How can I contact Predictive Oncology? Predictive Oncology's mailing address is 2915 COMMERS DRIVE SUITE 900, EAGAN MN, 55121. The official website for the company is www.precisiontherapeutics.com. The medical instruments supplier can be reached via phone at (651) 389-4800 or via email at james@haydenir.com. This page (NASDAQ:POAI) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Predictive Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.